Anuradha Chirala, MD
Cardiovascular Disease (Cardiology) · Morgan Hill
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 9 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
29 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chirala’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A55594 · Current
Licensed to practise in California · since 1996 · expires 2028-01-31 · Andhra University, Andhra Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$1,320,948
Medicare paid this office $1,320,948 for 575 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 384 | $210,770 | $53 |
| Return visit (30+ min) | 511 | $191,400 | $111 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 388 | $185,152 | $49 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 211 | $161,354 | $47 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 134 | $128,181 | $909 |
See all 33 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 384 | $210,770 | $53 |
| Return visit (30+ min) | 511 | $191,400 | $111 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 388 | $185,152 | $49 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 211 | $161,354 | $47 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 134 | $128,181 | $909 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 211 | $122,460 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 249 | $49,974 | $194 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 107 | $49,700 | $464 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 236 | $38,467 | $38 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 34 | $28,758 | $98 |
| Short return visit (20+ min) | 212 | $24,065 | $74 |
| Long return visit (40+ min) | 91 | $19,378 | $156 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 11 | $17,318 | $1,574 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 106 | $9,743 | $46 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 11 | $9,020 | $410 |
| New patient visit (45+ min) | 65 | $8,464 | $130 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 122 | $7,687 | $63 |
| Transitional care management services for problem of high complexity | 27 | $7,654 | $273 |
| Programming of dual lead pacemaker system | 39 | $4,371 | $74 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 12 | $3,747 | $58 |
| New patient visit (60+ min) | 18 | $3,211 | $178 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 134 | $3,208 | $23 |
| Sleep study including heart rate, breathing, airflow, and effort | 27 | $2,689 | $96 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,555 | $197 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 162 | $2,386 | $13 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 47 | $1,055 | $22 |
| Injection of drug or substance into vein | 25 | $966 | $39 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $922 | $26 |
| Injection, regadenoson, 0.1 mg | 50 | $732 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 12 | $715 | $24 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 11 | $210 | None |
| Infusion, normal saline solution, 250 cc | 118 | $129 | None |
| Injection, aminophyllin, up to 250 mg | 12 | $67 | None |
Who their Medicare patients are
575 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 16% · Women 57% · Also on Medicaid 11% · Health risk score 1.41. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 75% · Diabetes 35% · Heart failure 34% · Atrial fibrillation 32% · Chronic kidney disease 21% · Depression 18% · Cancer 17% · COPD 12% · Stroke 10% · Dementia 9%.
The office billed $3,582,859, Medicare allowed $1,705,006 and paid $1,320,948; for 19,389 services of 48 kinds; $1,138 of it was for drugs given in the office and $1,319,811 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 575 | 19,389 | 76 | 1.41 | $3,582,859 | $1,320,948 |
| 2023 | 587 | 21,200 | 76 | 1.32 | $3,567,320 | $1,356,862 |
| 2022 | 634 | 18,594 | 76 | 1.30 | $3,385,222 | $1,305,687 |
| 2021 | 631 | 20,528 | 76 | 1.34 | $3,672,371 | $1,446,762 |
| 2020 | 613 | 13,099 | 76 | 1.59 | $2,572,844 | $938,653 |
| 2019 | 610 | 9,802 | 76 | 1.55 | $2,040,488 | $701,714 |
| 2018 | 564 | 6,558 | 76 | 1.71 | $1,416,839 | $432,597 |
| 2017 | 617 | 5,336 | 76 | 1.70 | $1,316,410 | $396,959 |
| 2016 | 707 | 6,784 | 76 | 1.74 | $1,748,287 | $535,050 |
| 2015 | 1,029 | 6,919 | 75 | 1.89 | $1,921,471 | $599,202 |
| 2014 | 1,048 | 7,963 | 75 | 1.58 | $2,100,109 | $644,940 |
| 2013 | 707 | 5,156 | 75 | 1.44 | $1,886,156 | $567,465 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 404 | $214,457 | $56 |
| Return visit (30+ min) | 493 | $188,873 | $113 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 399 | $171,183 | $49 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 119 | $116,682 | $956 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 247 | $115,599 | $60 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 247 | $98,878 | $47 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 48 | $80,430 | $1,609 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 225 | $48,413 | $203 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 48 | $41,741 | $417 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 81 | $38,383 | $474 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 263 | $38,042 | $39 |
| Long return visit (40+ min) | 141 | $35,603 | $158 |
| Short return visit (20+ min) | 260 | $34,727 | $79 |
| New patient visit (45+ min) | 77 | $11,461 | $149 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 77 | $8,939 | $58 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 45 | $8,815 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 130 | $8,797 | $67 |
| Transitional care management services for problem of high complexity | 22 | $7,445 | $276 |
| Injection of drug or substance into vein | 129 | $5,259 | $40 |
| Programming of dual lead pacemaker system | 35 | $4,465 | $76 |
| New patient visit (60+ min) | 18 | $3,813 | $212 |
| Sleep study including heart rate, breathing, airflow, and effort | 32 | $3,091 | $88 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 119 | $2,879 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 149 | $2,419 | $14 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 72 | $1,423 | None |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 44 | $937 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $904 | $65 |
| Infusion, normal saline solution, 250 cc | 128 | $417 | None |
2022: 28 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 459 | $265,500 | $61 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 457 | $187,474 | $50 |
| Return visit (30+ min) | 545 | $181,931 | $114 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 128 | $133,341 | $1,010 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 197 | $76,175 | $60 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 42 | $68,017 | $1,619 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 128 | $63,353 | $491 |
| Long return visit (40+ min) | 220 | $58,632 | $166 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 211 | $44,573 | $201 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 42 | $35,228 | $419 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 163 | $29,419 | $47 |
| Short return visit (20+ min) | 172 | $20,793 | $80 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 128 | $15,428 | $60 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 154 | $14,822 | $40 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 171 | $11,357 | $66 |
| New patient visit (45+ min) | 71 | $9,448 | $133 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 45 | $8,242 | $24 |
| Transitional care management services for problem of high complexity | 20 | $6,064 | $276 |
| New patient visit (60+ min) | 22 | $4,256 | $193 |
| Programming of dual lead pacemaker system | 32 | $4,116 | $79 |
| Sleep study including heart rate, breathing, airflow, and effort | 35 | $3,414 | $88 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 128 | $3,170 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 152 | $2,169 | $13 |
| Injection of drug or substance into vein | 48 | $2,051 | $43 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 22 | $1,556 | $71 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 60 | $1,264 | $21 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 73 | $1,240 | None |
| Infusion, normal saline solution, 250 cc | 170 | $252 | None |
2021: 31 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 465 | $270,692 | $70 |
| Return visit (30+ min) | 523 | $206,837 | $116 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 451 | $176,363 | $51 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 69 | $114,727 | $1,663 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 136 | $111,625 | $797 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 228 | $81,516 | $40 |
| Long return visit (40+ min) | 250 | $74,526 | $168 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 285 | $63,064 | $215 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 69 | $57,399 | $422 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 327 | $54,443 | $40 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 99 | $51,573 | $521 |
| Short return visit (20+ min) | 215 | $29,418 | $77 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 98 | $19,183 | $98 |
| New patient visit (45+ min) | 84 | $12,625 | $150 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 172 | $11,552 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 399 | $6,602 | $14 |
| New patient visit (60+ min) | 28 | $5,834 | $208 |
| Programming of dual lead pacemaker system | 37 | $4,557 | $71 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 137 | $3,385 | $24 |
| Transitional care management services for problem of high complexity | 11 | $3,343 | $279 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 152 | $3,333 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 37 | $3,037 | $80 |
| Injection of drug or substance into vein | 67 | $3,010 | $45 |
| Sleep study including heart rate, breathing, airflow, and effort | 28 | $2,962 | $102 |
| Ultrasound of both sides of head and neck blood flow | 12 | $2,641 | $220 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 92 | $1,894 | None |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 36 | $1,761 | $25 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 15 | $1,087 | $27 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 12 | $751 | $63 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $735 | $37 |
| Infusion, normal saline solution, 250 cc | 168 | $359 | None |
2020: 35 services
| Return visit (30+ min) | 436 | $117,905 | $100 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 316 | $94,356 | $40 |
| Insertion of heart rhythm monitor under skin | 16 | $90,437 | $5,652 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 317 | $79,199 | $69 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 42 | $70,131 | $1,670 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 85 | $66,983 | $779 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | $51,898 | $212 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 95 | $48,247 | $508 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 291 | $45,306 | $51 |
| Telephone medical discussion with physician, 21-30 minutes | 230 | $44,881 | $107 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 42 | $35,321 | $420 |
| Long return visit (40+ min) | 136 | $28,911 | $138 |
| Short return visit (20+ min) | 255 | $27,267 | $66 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 95 | $18,459 | $98 |
| Telephone medical discussion with physician, 11-20 minutes | 159 | $17,213 | $75 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 184 | $16,309 | $41 |
| New patient visit (45+ min) | 69 | $10,525 | $153 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 142 | $9,390 | $66 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 281 | $5,874 | $21 |
| Programming of dual lead pacemaker system | 40 | $4,211 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 206 | $3,760 | $16 |
| New patient visit (60+ min) | 24 | $3,734 | $156 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 52 | $3,466 | $65 |
| Transitional care management services for problem of high complexity | 12 | $3,005 | $231 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,809 | $216 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,805 | $187 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 32 | $2,789 | $87 |
| Sleep study including heart rate, breathing, airflow, and effort | 21 | $2,588 | $118 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 85 | $2,123 | $25 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 17 | $2,095 | $23 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 17 | $2,076 | $23 |
| Injection of drug or substance into vein | 41 | $1,732 | $42 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 66 | $1,535 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 23 | $275 | $8 |
| Infusion, normal saline solution, 250 cc | 135 | $218 | None |
2019: 32 services
| Return visit (30+ min) | 442 | $115,555 | $99 |
| Insertion of heart rhythm monitor under skin | 17 | $96,336 | $5,667 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 49 | $76,190 | $1,555 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 82 | $64,987 | $774 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 104 | $52,152 | $501 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $50,173 | $206 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 49 | $40,731 | $416 |
| Short return visit (20+ min) | 322 | $39,635 | $65 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 330 | $36,008 | $40 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 104 | $20,052 | $96 |
| Long return visit (40+ min) | 84 | $16,857 | $137 |
| New patient visit (45+ min) | 90 | $12,731 | $141 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 166 | $11,033 | $65 |
| Electronic analysis of pacemaker to correct rapid heart rate | 11 | $6,635 | $255 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $6,478 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $6,260 | $184 |
| Transitional care management services for problem of high complexity | 20 | $5,589 | $215 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 61 | $5,076 | $79 |
| Sleep study including heart rate, breathing, airflow, and effort | 31 | $4,627 | $140 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 247 | $4,561 | $16 |
| Programming of dual lead pacemaker system | 42 | $4,136 | $58 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,691 | $205 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 73 | $2,421 | None |
| Transitional care management services for problem of at least moderate complexity | 16 | $2,410 | $151 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 84 | $2,041 | $24 |
| Injection of drug or substance into vein | 48 | $1,963 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,656 | $66 |
| Programming of single lead pacemaker system | 13 | $1,152 | $55 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 16 | $997 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 37 | $542 | $8 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 16 | $540 | $13 |
| Infusion, normal saline solution, 250 cc | 152 | $239 | None |
2018: 29 services
| Return visit (30+ min) | 369 | $85,441 | $98 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 69 | $56,283 | $782 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 86 | $43,817 | $510 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 200 | $43,570 | $208 |
| Short return visit (20+ min) | 329 | $32,517 | $62 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 20 | $30,861 | $1,543 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 86 | $16,265 | $95 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 20 | $15,639 | $391 |
| New patient visit (45+ min) | 71 | $10,427 | $147 |
| Transitional care management services for problem of high complexity | 35 | $9,336 | $222 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 117 | $7,416 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $6,072 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,867 | $178 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 62 | $5,598 | $85 |
| Long return visit (40+ min) | 32 | $4,853 | $131 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 239 | $4,398 | $16 |
| Programming of dual lead pacemaker system | 41 | $3,924 | $52 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,842 | $213 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,942 | $65 |
| Injection, regadenoson, 0.1 mg | 16 | $2,704 | None |
| Transitional care management services for problem of at least moderate complexity | 14 | $2,207 | $158 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 49 | $1,723 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 69 | $1,691 | $23 |
| New patient visit (30+ min) | 18 | $1,517 | $84 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,383 | $99 |
| Programming of single lead pacemaker system | 13 | $1,145 | $46 |
| Injection of drug or substance into vein | 20 | $963 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 32 | $797 | $8 |
| Infusion, normal saline solution, 250 cc | 105 | $114 | None |
2017: 28 services
| Return visit (30+ min) | 364 | $76,751 | $96 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 78 | $60,509 | $766 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 195 | $46,410 | $227 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 92 | $45,389 | $493 |
| Short return visit (20+ min) | 383 | $34,937 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 90 | $17,175 | $95 |
| Long return visit (40+ min) | 69 | $12,074 | $128 |
| New patient visit (45+ min) | 56 | $7,579 | $135 |
| Transitional care management services for problem of high complexity | 31 | $7,481 | $220 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 103 | $6,752 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 305 | $6,042 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 95 | $5,508 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,895 | $181 |
| Ultrasound of leg arteries or artery grafts | 18 | $4,818 | $268 |
| Programming of dual lead pacemaker system | 49 | $4,411 | $49 |
| Ultrasound of both sides of head and neck blood flow | 19 | $4,181 | $209 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 46 | $3,970 | $79 |
| New patient visit (30+ min) | 39 | $3,881 | $100 |
| Sleep study including heart rate, breathing, airflow, and effort | 21 | $3,181 | $151 |
| Transitional care management services for problem of at least moderate complexity | 14 | $2,341 | $156 |
| Injection, regadenoson, 0.1 mg | 13 | $2,256 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 78 | $1,853 | $23 |
| Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | 25 | $1,489 | $60 |
| Programming of single lead pacemaker system | 11 | $876 | $46 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 32 | $799 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 35 | $509 | $8 |
| Infusion, normal saline solution, 250 cc | 100 | $62 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 60 | $8 | None |
2016: 31 services
| Return visit (30+ min) | 442 | $113,099 | $95 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 105 | $85,921 | $760 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 270 | $70,038 | $227 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 131 | $64,234 | $490 |
| Short return visit (20+ min) | 324 | $26,238 | $59 |
| Long return visit (40+ min) | 111 | $22,965 | $133 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 74 | $12,805 | $87 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 57 | $10,598 | $93 |
| Ultrasound of both sides of head and neck blood flow | 48 | $9,444 | $197 |
| New patient visit (45+ min) | 63 | $9,127 | $145 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 137 | $8,895 | $64 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 82 | $6,907 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $6,904 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,309 | $180 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 309 | $6,302 | $16 |
| Transitional care management services for problem of high complexity | 21 | $4,818 | $219 |
| Ultrasound of leg arteries or artery grafts | 22 | $4,315 | $196 |
| Sleep study including heart rate, breathing, airflow, and effort | 25 | $4,233 | $169 |
| Programming of dual lead pacemaker system | 49 | $3,869 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,261 | $64 |
| New patient visit (30+ min) | 34 | $3,251 | $96 |
| Transitional care management services for problem of at least moderate complexity | 18 | $2,963 | $156 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 106 | $2,670 | $23 |
| Injection, regadenoson, 0.1 mg | 13 | $2,116 | None |
| Programming of single lead pacemaker system | 32 | $2,010 | $45 |
| New patient visit (60+ min) | 11 | $1,954 | $178 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,525 | $109 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 49 | $1,247 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 38 | $713 | $8 |
| Infusion, normal saline solution, 250 cc | 131 | $49 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 71 | $10 | None |
2015: 30 services
| Return visit (30+ min) | 482 | $122,481 | $95 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 137 | $100,638 | $714 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 167 | $83,421 | $497 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 299 | $70,673 | $222 |
| Short return visit (20+ min) | 382 | $38,779 | $63 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 167 | $29,185 | $87 |
| New patient visit (45+ min) | 86 | $12,402 | $144 |
| Ultrasound of both sides of head and neck blood flow | 57 | $11,600 | $204 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 175 | $11,547 | $65 |
| Long return visit (40+ min) | 63 | $10,034 | $129 |
| Ultrasound of leg arteries or artery grafts | 40 | $9,161 | $229 |
| Transitional care management services for problem of high complexity | 38 | $8,741 | $213 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 102 | $8,676 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 139 | $8,251 | $56 |
| Sleep study including heart rate, breathing, airflow, and effort | 44 | $7,546 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,318 | $178 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 301 | $5,987 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 417 | $5,213 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,081 | $65 |
| Programming of dual lead pacemaker system | 53 | $3,971 | $49 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 137 | $3,290 | $23 |
| Transitional care management services for problem of at least moderate complexity | 16 | $2,543 | $150 |
| New patient visit (30+ min) | 24 | $2,126 | $89 |
| Injection, regadenoson, 0.1 mg | 12 | $1,864 | None |
| Programming of single lead pacemaker system | 26 | $1,839 | $44 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,616 | $108 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 56 | $887 | None |
| Short return visit | 11 | $419 | $38 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 19 | $270 | $11 |
| Infusion, normal saline solution, 250 cc | 167 | $52 | None |
2014: 31 services
| Return visit (30+ min) | 534 | $139,128 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 192 | $95,490 | $490 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 132 | $92,650 | $697 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 341 | $80,781 | $226 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 192 | $33,661 | $86 |
| Short return visit (20+ min) | 315 | $25,681 | $58 |
| New patient visit (45+ min) | 120 | $17,020 | $142 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $13,490 | $180 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 200 | $12,895 | $63 |
| Ultrasound of leg arteries or artery grafts | 50 | $11,742 | $235 |
| Ultrasound of both sides of head and neck blood flow | 46 | $9,232 | $196 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 105 | $8,800 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 128 | $7,808 | $57 |
| Long return visit (40+ min) | 48 | $7,771 | $130 |
| Transitional care management services for problem of high complexity | 27 | $6,186 | $213 |
| Electronic analysis of pacemaker to correct rapid heart rate | 12 | $5,527 | $240 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 443 | $5,367 | $8 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 303 | $5,179 | $15 |
| Programming of dual lead pacemaker system | 53 | $4,899 | $51 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 51 | $4,409 | None |
| New patient visit (30+ min) | 41 | $3,503 | $85 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 134 | $3,135 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,754 | $64 |
| Injection, regadenoson, 0.1 mg | 14 | $2,321 | None |
| Critical care, first 30-74 minutes | 11 | $2,150 | $195 |
| Transitional care management services for problem of at least moderate complexity | 13 | $2,003 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,756 | $92 |
| Programming of single lead pacemaker system | 15 | $996 | $37 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 15 | $281 | $8 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 13 | $165 | $11 |
| Infusion, normal saline solution, 250 cc | 191 | $50 | None |
2013: 31 services
| Return visit (30+ min) | 525 | $142,466 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 176 | $90,981 | $511 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 323 | $63,883 | $185 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 77 | $59,364 | $771 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 183 | $32,197 | $87 |
| Short return visit (20+ min) | 280 | $24,783 | $59 |
| New patient visit (45+ min) | 128 | $17,707 | $138 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 187 | $13,243 | $69 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 59 | $10,631 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,535 | $165 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 116 | $9,929 | $83 |
| Ultrasound of leg arteries or artery grafts | 47 | $9,248 | $193 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 35 | $7,578 | $217 |
| Long return visit (40+ min) | 34 | $6,750 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $6,194 | $63 |
| Ultrasound of both sides of head and neck blood flow | 32 | $5,759 | $180 |
| Electronic analysis of pacemaker to correct rapid heart rate | 14 | $5,704 | $238 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 296 | $5,615 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $5,013 | $51 |
| Injection, regadenoson, 0.1 mg | 26 | $4,406 | None |
| Programming of dual lead pacemaker system | 46 | $3,416 | $52 |
| New patient visit (30+ min) | 32 | $2,680 | $84 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 76 | $1,682 | $22 |
| Programming of single lead pacemaker system | 18 | $1,282 | $41 |
| Extended office or other outpatient service, first hour | 13 | $1,237 | $88 |
| Extended office or other outpatient service, each additional 30 minutes | 13 | $1,206 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 48 | $885 | $7 |
| Hospital discharge day management, 30 minutes or less | 12 | $770 | $64 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 17 | $243 | $12 |
| Infusion, normal saline solution, 250 cc | 183 | $41 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 46 | $6 | None |
Medicaid work
$5,274 in 2024
Medicaid paid $5,274 for 1,090 billed services this clinician did in 2024, up to 210 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 648 | $3,565 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 204 | $1,104 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 196 | $369 |
| Return visit (30+ min) | 42 | $237 |
| 2024 | 1,090 | 4 | 210 | $5,274 |
| 2023 | 1,329 | 4 | 228 | $5,814 |
| 2022 | 1,080 | 4 | 170 | $5,206 |
| 2021 | 827 | 2 | 191 | $7,029 |
| 2020 | 445 | 2 | 68 | $3,608 |
| 2019 | 31 | 1 | 16 | $683 |
| 2018 | 41 | 1 | 14 | $1,341 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 932 | $4,198 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 185 | $779 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 167 | $503 |
| Return visit (30+ min) | 45 | $335 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 776 | $4,694 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 171 | $245 |
| Return visit (30+ min) | 12 | $163 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 121 | $105 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 706 | $6,256 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 121 | $772 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 298 | $3,182 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 147 | $426 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 31 | $683 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 41 | $1,341 |
Drugs they prescribed that Part D paid
$1,372,506
Pharmacies billed $1,372,506 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 9,596) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
8,119 generic and 1,477 brand-name prescriptions · $1,372,506 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 586 | $598,663 | $1,022 |
| Jardiance | 193 | $182,669 | $946 |
| Repatha Sureclick | 204 | $177,206 | $869 |
| Entresto | 108 | $111,211 | $1,030 |
| Xarelto | 71 | $62,975 | $887 |
See all 64 drugs
| Eliquis | 586 | $598,663 | $1,022 |
| Jardiance | 193 | $182,669 | $946 |
| Repatha Sureclick | 204 | $177,206 | $869 |
| Entresto | 108 | $111,211 | $1,030 |
| Xarelto | 71 | $62,975 | $887 |
| Veltassa | 23 | $26,961 | $1,172 |
| Farxiga | 11 | $12,717 | $1,156 |
| Nebivolol | 224 | $12,648 | $56 |
| Metoprolol | 915 | $11,321 | $12 |
| Edarbi | 23 | $10,022 | $436 |
| Ezetimibe | 505 | $9,931 | $20 |
| Atorvastatin | 1,159 | $9,840 | $8 |
| Rosuvastatin | 405 | $9,375 | $23 |
| Icosapent Ethyl | 27 | $7,031 | $260 |
| Isosorbide Mononitrate Er | 446 | $6,897 | $15 |
| Vascepa | 12 | $6,568 | $547 |
| Livalo | 14 | $5,639 | $403 |
| Amlodipine Besylate | 785 | $5,206 | $7 |
| Losartan | 554 | $4,455 | $8 |
| Ranolazine Er | 46 | $4,365 | $95 |
| Hydralazine | 263 | $3,982 | $15 |
| Furosemide | 399 | $3,487 | $9 |
| Nitroglycerin | 225 | $2,874 | $13 |
| Carvedilol | 256 | $2,573 | $10 |
| Diltiazem 12hr Er | 12 | $2,251 | $188 |
| Valsartan | 87 | $2,089 | $24 |
| Potassium Chloride | 97 | $1,906 | $20 |
| Amiodarone | 69 | $1,749 | $25 |
| Digoxin | 63 | $1,683 | $27 |
| Diltiazem 24hr Er (Cd) | 67 | $1,647 | $25 |
| Losartan-Hydrochlorothiazide | 122 | $1,614 | $13 |
| Dilt-Xr | 47 | $1,550 | $33 |
| Diltiazem 24hr Er | 43 | $1,477 | $34 |
| Lisinopril | 237 | $1,432 | $6 |
| Diltiazem 24hr Er (Xr) | 60 | $1,407 | $23 |
| Spironolactone | 83 | $1,397 | $17 |
| Amlodipine Besylate-Benazepril | 103 | $1,346 | $13 |
| Valsartan-Hydrochlorothiazide | 21 | $1,185 | $56 |
| Bumetanide | 39 | $1,177 | $30 |
| Sotalol | 56 | $1,172 | $21 |
| Propafenone | 20 | $972 | $49 |
| Diltiazem | 38 | $815 | $21 |
| Metoprolol | 122 | $715 | $6 |
| Flecainide Acetate | 24 | $660 | $28 |
| Olmesartan Medoxomil | 20 | $635 | $32 |
| Hydrochlorothiazide | 145 | $570 | $4 |
| Nifedipine Er | 15 | $548 | $37 |
| Amlodipine-Valsartan | 21 | $542 | $26 |
| Clopidogrel | 32 | $541 | $17 |
| Benazepril | 42 | $476 | $11 |
| Eplerenone | 17 | $403 | $24 |
| Fenofibrate | 13 | $365 | $28 |
| Nitroglycerin Patch | 12 | $296 | $25 |
| Simvastatin | 22 | $252 | $11 |
| Lisinopril-Hydrochlorothiazide | 35 | $239 | $7 |
| Propafenone Hcl Er | 12 | $233 | $19 |
| Chlorthalidone | 24 | $217 | $9 |
| Verapamil Er | 22 | $196 | $9 |
| Pantoprazole | 21 | $136 | $6 |
| Pravastatin | 18 | $107 | $6 |
| Atenolol | 17 | $70 | $4 |
| Metformin | 14 | $53 | $4 |
| Verapamil | 12 | $47 | $4 |
| Meclizine | 11 | $43 | $4 |
Year by year
| 2024 | 9,596 | 724 | 0% (0) | 15% | $1,372,506 |
| 2023 | 9,794 | 690 | 0% (0) | 14% | $1,358,018 |
| 2022 | 9,567 | 690 | 0% (0) | 16% | $1,177,574 |
| 2021 | 9,516 | 679 | 0% (0) | 20% | $1,104,285 |
| 2020 | 8,745 | 635 | 0% (0) | 21% | $961,543 |
| 2019 | 8,031 | 612 | 0% (0) | 19% | $803,417 |
| 2018 | 8,781 | 588 | None | 20% | $754,960 |
| 2017 | 10,423 | 622 | 0% (0) | 26% | $810,587 |
| 2016 | 12,104 | 642 | 0% (0) | 27% | $835,831 |
| 2015 | 10,733 | 645 | 0% (0) | None | $715,756 |
| 2014 | 9,364 | 609 | 0% (0) | None | $656,063 |
| 2013 | 8,477 | 538 | 0% (0) | None | $619,108 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 65 drugs
| Eliquis | 577 | $564,729 | $979 |
| Repatha Sureclick | 217 | $171,808 | $792 |
| Jardiance | 131 | $140,130 | $1,070 |
| Entresto | 94 | $94,597 | $1,006 |
| Xarelto | 94 | $88,322 | $940 |
| Praluent | 21 | $21,626 | $1,030 |
| Ezetimibe | 469 | $20,852 | $44 |
| Metoprolol | 881 | $15,125 | $17 |
| Atorvastatin | 1,178 | $14,318 | $12 |
| Nebivolol | 161 | $13,700 | $85 |
| Veltassa | 12 | $13,344 | $1,112 |
| Vascepa | 29 | $11,863 | $409 |
| Ranolazine Er | 72 | $10,527 | $146 |
| Icosapent Ethyl | 28 | $9,638 | $344 |
| Isosorbide Mononitrate Er | 433 | $9,319 | $22 |
| Rosuvastatin | 392 | $9,097 | $23 |
| Dabigatran Etexilate | 16 | $7,591 | $474 |
| Amlodipine Besylate | 755 | $6,306 | $8 |
| Edarbi | 16 | $5,783 | $361 |
| Losartan | 500 | $5,384 | $11 |
| Edarbyclor | 13 | $5,027 | $387 |
| Hydralazine | 291 | $4,858 | $17 |
| Diltiazem 24hr Er (Xr) | 101 | $4,214 | $42 |
| Bumetanide | 71 | $4,105 | $58 |
| Carvedilol | 309 | $4,104 | $13 |
| Amiodarone | 103 | $4,079 | $40 |
| Potassium Chloride | 139 | $3,957 | $28 |
| Digoxin | 87 | $3,420 | $39 |
| Diltiazem 24hr Er (Cd) | 102 | $3,399 | $33 |
| Furosemide | 413 | $3,189 | $8 |
| Valsartan | 88 | $3,055 | $35 |
| Nitroglycerin | 223 | $2,899 | $13 |
| Diltiazem 12hr Er | 12 | $2,386 | $199 |
| Lisinopril | 245 | $2,106 | $9 |
| Amlodipine Besylate-Benazepril | 90 | $1,910 | $21 |
| Valsartan-Hydrochlorothiazide | 35 | $1,782 | $51 |
| Diltiazem 24hr Er | 48 | $1,752 | $37 |
| Losartan-Hydrochlorothiazide | 132 | $1,736 | $13 |
| Diltiazem | 60 | $1,522 | $25 |
| Metoprolol | 114 | $1,517 | $13 |
| Eplerenone | 22 | $1,511 | $69 |
| Propafenone | 15 | $1,398 | $93 |
| Sotalol | 56 | $1,272 | $23 |
| Olmesartan Medoxomil | 34 | $1,118 | $33 |
| Clopidogrel | 47 | $939 | $20 |
| Flecainide Acetate | 12 | $929 | $77 |
| Chlorthalidone | 32 | $920 | $29 |
| Hydrochlorothiazide | 168 | $887 | $5 |
| Spironolactone | 108 | $816 | $8 |
| Dilt-Xr | 19 | $788 | $41 |
| Fenofibrate | 19 | $627 | $33 |
| Nifedipine Er | 12 | $564 | $47 |
| Levothyroxine | 27 | $564 | $21 |
| Lisinopril-Hydrochlorothiazide | 51 | $496 | $10 |
| Midodrine | 12 | $420 | $35 |
| Warfarin | 16 | $411 | $26 |
| Verapamil Er | 23 | $372 | $16 |
| Benazepril | 35 | $313 | $9 |
| Nitroglycerin Patch | 11 | $287 | $26 |
| Atenolol | 18 | $252 | $14 |
| Sotalol Af | 13 | $212 | $16 |
| Bisoprolol | 14 | $202 | $14 |
| Metformin | 12 | $154 | $13 |
| Pantoprazole | 19 | $152 | $8 |
| Simvastatin | 25 | $138 | $6 |
2022: 67 drugs
| Eliquis | 654 | $513,818 | $786 |
| Repatha Sureclick | 224 | $155,415 | $694 |
| Xarelto | 93 | $90,333 | $971 |
| Entresto | 91 | $78,638 | $864 |
| Praluent | 37 | $28,792 | $778 |
| Ezetimibe | 427 | $23,788 | $56 |
| Pradaxa | 28 | $19,641 | $701 |
| Veltassa | 13 | $18,389 | $1,415 |
| Ranolazine Er | 95 | $15,183 | $160 |
| Nebivolol | 141 | $15,147 | $107 |
| Vascepa | 30 | $14,291 | $476 |
| Metoprolol | 851 | $13,155 | $15 |
| Atorvastatin | 1,175 | $12,517 | $11 |
| Bumetanide | 111 | $11,007 | $99 |
| Rosuvastatin | 381 | $7,983 | $21 |
| Brilinta | 13 | $7,689 | $591 |
| Isosorbide Mononitrate Er | 418 | $7,291 | $17 |
| Edarbyclor | 12 | $5,948 | $496 |
| Icosapent Ethyl | 14 | $5,836 | $417 |
| Potassium Chloride | 162 | $5,382 | $33 |
| Amlodipine Besylate | 755 | $5,371 | $7 |
| Losartan | 475 | $4,785 | $10 |
| Hydralazine | 256 | $4,225 | $17 |
| Amiodarone | 85 | $3,916 | $46 |
| Diltiazem 24hr Er (Cd) | 113 | $3,853 | $34 |
| Digoxin | 110 | $3,735 | $34 |
| Valsartan | 80 | $3,702 | $46 |
| Diltiazem 12hr Er | 14 | $3,592 | $257 |
| Bystolic | 11 | $3,505 | $319 |
| Nitroglycerin | 218 | $3,419 | $16 |
| Carvedilol | 267 | $3,259 | $12 |
| Furosemide | 386 | $2,730 | $7 |
| Losartan-Hydrochlorothiazide | 120 | $2,216 | $18 |
| Dilt-Xr | 61 | $1,994 | $33 |
| Diltiazem 24hr Er | 54 | $1,749 | $32 |
| Amlodipine Besylate-Benazepril | 80 | $1,697 | $21 |
| Diltiazem 24hr Er (Xr) | 50 | $1,630 | $33 |
| Chlorthalidone | 56 | $1,508 | $27 |
| Matzim La | 12 | $1,495 | $125 |
| Valsartan-Hydrochlorothiazide | 34 | $1,441 | $42 |
| Lisinopril | 228 | $1,370 | $6 |
| Clopidogrel | 84 | $1,350 | $16 |
| Spironolactone | 106 | $1,231 | $12 |
| Telmisartan | 12 | $1,217 | $101 |
| Olmesartan Medoxomil | 31 | $1,119 | $36 |
| Metoprolol | 100 | $999 | $10 |
| Propafenone | 12 | $891 | $74 |
| Sotalol | 47 | $810 | $17 |
| Diltiazem | 63 | $794 | $13 |
| Hydrochlorothiazide | 143 | $761 | $5 |
| Fenofibrate | 14 | $635 | $45 |
| Lisinopril-Hydrochlorothiazide | 61 | $601 | $10 |
| Nifedipine Er | 12 | $573 | $48 |
| Benazepril | 30 | $527 | $18 |
| Klor-Con 10 | 18 | $462 | $26 |
| Levothyroxine | 23 | $381 | $17 |
| Nitroglycerin Patch | 18 | $293 | $16 |
| Warfarin | 19 | $290 | $15 |
| Torsemide | 11 | $289 | $26 |
| Olmesartan-Hydrochlorothiazide | 20 | $252 | $13 |
| Pantoprazole | 15 | $210 | $14 |
| Omeprazole | 11 | $210 | $19 |
| Mirtazapine | 12 | $205 | $17 |
| Simvastatin | 23 | $187 | $8 |
| Benazepril-Hydrochlorothiazide | 11 | $112 | $10 |
| Atenolol | 15 | $88 | $6 |
| Meclizine | 11 | $69 | $6 |
2021: 68 drugs
| Eliquis | 614 | $430,303 | $701 |
| Entresto | 149 | $91,884 | $617 |
| Repatha Sureclick | 172 | $91,600 | $533 |
| Xarelto | 114 | $89,566 | $786 |
| Bystolic | 157 | $50,680 | $323 |
| Vascepa | 60 | $28,682 | $478 |
| Pradaxa | 33 | $24,713 | $749 |
| Brilinta | 32 | $20,138 | $629 |
| Praluent | 34 | $17,396 | $512 |
| Bumetanide | 163 | $14,629 | $90 |
| Ezetimibe | 265 | $14,536 | $55 |
| Ranolazine Er | 107 | $14,294 | $134 |
| Metoprolol | 801 | $13,409 | $17 |
| Veltassa | 11 | $12,524 | $1,139 |
| Atorvastatin | 1,046 | $12,374 | $12 |
| Jardiance | 18 | $10,861 | $603 |
| Rosuvastatin | 328 | $8,117 | $25 |
| Repatha | 18 | $7,979 | $443 |
| Edarbyclor | 19 | $7,858 | $414 |
| Isosorbide Mononitrate Er | 405 | $6,532 | $16 |
| Amlodipine Besylate | 742 | $6,253 | $8 |
| Livalo | 15 | $5,958 | $397 |
| Potassium Chloride | 167 | $5,154 | $31 |
| Losartan | 458 | $4,880 | $11 |
| Dilt-Xr | 80 | $4,664 | $58 |
| Digoxin | 157 | $4,656 | $30 |
| Diltiazem 24hr Er (Cd) | 146 | $4,634 | $32 |
| Diltiazem 12hr Er | 21 | $4,399 | $209 |
| Hydralazine | 255 | $4,006 | $16 |
| Valsartan | 69 | $3,753 | $54 |
| Carvedilol | 308 | $3,428 | $11 |
| Nebivolol | 20 | $3,385 | $169 |
| Furosemide | 445 | $2,928 | $7 |
| Nitroglycerin | 167 | $2,633 | $16 |
| Chlorthalidone | 90 | $2,387 | $27 |
| Losartan-Hydrochlorothiazide | 116 | $2,314 | $20 |
| Valsartan-Hydrochlorothiazide | 43 | $2,170 | $50 |
| Amiodarone | 71 | $2,093 | $29 |
| Diltiazem 24hr Er | 50 | $2,064 | $41 |
| Amlodipine Besylate-Benazepril | 92 | $1,995 | $22 |
| Omega-3 Acid Ethyl Esters | 12 | $1,691 | $141 |
| Olmesartan Medoxomil | 39 | $1,626 | $42 |
| Sotalol | 77 | $1,451 | $19 |
| Lisinopril | 232 | $1,313 | $6 |
| Spironolactone | 114 | $1,230 | $11 |
| Propafenone | 15 | $1,151 | $77 |
| Flecainide Acetate | 15 | $1,132 | $75 |
| Clopidogrel | 84 | $1,085 | $13 |
| Diltiazem | 85 | $1,052 | $12 |
| Metoprolol | 90 | $1,002 | $11 |
| Nifedipine Er | 21 | $886 | $42 |
| Hydrochlorothiazide | 139 | $847 | $6 |
| Cartia Xt | 15 | $828 | $55 |
| Isosorbide Dinitrate | 13 | $787 | $61 |
| Nitroglycerin Patch | 18 | $747 | $42 |
| Fenofibrate | 15 | $742 | $49 |
| Bisoprolol | 21 | $728 | $35 |
| Lisinopril-Hydrochlorothiazide | 58 | $549 | $9 |
| Klor-Con 10 | 24 | $442 | $18 |
| Omeprazole | 31 | $383 | $12 |
| Olmesartan-Hydrochlorothiazide | 17 | $383 | $23 |
| Simvastatin | 37 | $362 | $10 |
| Warfarin | 23 | $245 | $11 |
| Torsemide | 16 | $230 | $14 |
| Benazepril | 17 | $182 | $11 |
| Benazepril-Hydrochlorothiazide | 12 | $165 | $14 |
| Levothyroxine | 11 | $153 | $14 |
| Pantoprazole | 13 | $143 | $11 |
2020: 67 drugs
| Eliquis | 618 | $399,917 | $647 |
| Xarelto | 114 | $89,335 | $784 |
| Entresto | 118 | $71,075 | $602 |
| Bystolic | 212 | $56,666 | $267 |
| Vascepa | 64 | $30,628 | $479 |
| Repatha Sureclick | 64 | $29,277 | $457 |
| Pradaxa | 36 | $27,862 | $774 |
| Brilinta | 32 | $18,855 | $589 |
| Metoprolol | 766 | $15,769 | $21 |
| Ranolazine Er | 141 | $14,865 | $105 |
| Bumetanide | 175 | $12,333 | $70 |
| Atorvastatin | 760 | $11,101 | $15 |
| Rosuvastatin | 289 | $10,512 | $36 |
| Edarbyclor | 28 | $9,865 | $352 |
| Ezetimibe | 133 | $7,924 | $60 |
| Digoxin | 207 | $6,446 | $31 |
| Repatha Pushtronex | 12 | $5,903 | $492 |
| Losartan-Hydrochlorothiazide | 123 | $5,740 | $47 |
| Livalo | 12 | $5,723 | $477 |
| Diltiazem 24hr Er (Cd) | 165 | $5,603 | $34 |
| Isosorbide Mononitrate Er | 342 | $5,579 | $16 |
| Edarbi | 12 | $5,519 | $460 |
| Diovan | 11 | $5,350 | $486 |
| Potassium Chloride | 167 | $5,242 | $31 |
| Losartan | 454 | $4,843 | $11 |
| Amlodipine Besylate | 643 | $4,317 | $7 |
| Nitroglycerin | 162 | $3,675 | $23 |
| Diltiazem 12hr Er | 19 | $3,359 | $177 |
| Carvedilol | 374 | $3,349 | $9 |
| Amiodarone | 92 | $3,268 | $36 |
| Dilt-Xr | 57 | $2,930 | $51 |
| Omega-3 Acid Ethyl Esters | 14 | $2,448 | $175 |
| Diltiazem 24hr Er | 56 | $2,430 | $43 |
| Furosemide | 337 | $2,279 | $7 |
| Flecainide Acetate | 16 | $2,119 | $132 |
| Valsartan-Hydrochlorothiazide | 38 | $2,097 | $55 |
| Hydralazine | 144 | $2,084 | $14 |
| Lisinopril | 269 | $1,986 | $7 |
| Amlodipine Besylate-Benazepril | 84 | $1,963 | $23 |
| Valsartan | 43 | $1,941 | $45 |
| Olmesartan Medoxomil | 51 | $1,881 | $37 |
| Sotalol | 83 | $1,862 | $22 |
| Spironolactone | 116 | $1,612 | $14 |
| Clopidogrel | 90 | $1,488 | $17 |
| Chlorthalidone | 51 | $1,480 | $29 |
| Fenofibrate | 22 | $1,456 | $66 |
| Diltiazem | 71 | $1,207 | $17 |
| Hydrochlorothiazide | 171 | $1,203 | $7 |
| Propafenone | 16 | $1,187 | $74 |
| Bisoprolol | 28 | $1,074 | $38 |
| Metoprolol | 92 | $1,030 | $11 |
| Cartia Xt | 21 | $826 | $39 |
| Telmisartan | 11 | $644 | $59 |
| Simvastatin | 60 | $626 | $10 |
| Nitroglycerin Patch | 13 | $583 | $45 |
| Nifedipine Er | 13 | $491 | $38 |
| Pravastatin | 30 | $467 | $16 |
| Benazepril | 36 | $430 | $12 |
| Omeprazole | 44 | $428 | $10 |
| Irbesartan-Hydrochlorothiazide | 11 | $342 | $31 |
| Lisinopril-Hydrochlorothiazide | 36 | $340 | $9 |
| Fenofibrate | 11 | $338 | $31 |
| Warfarin | 22 | $309 | $14 |
| Pantoprazole | 21 | $282 | $13 |
| Torsemide | 20 | $248 | $12 |
| Irbesartan | 11 | $230 | $21 |
| Atenolol | 12 | $127 | $11 |
2019: 71 drugs
| Eliquis | 478 | $297,595 | $623 |
| Xarelto | 136 | $87,276 | $642 |
| Bystolic | 194 | $46,690 | $241 |
| Entresto | 69 | $43,035 | $624 |
| Pradaxa | 51 | $30,513 | $598 |
| Ranexa | 53 | $25,891 | $489 |
| Vascepa | 50 | $25,086 | $502 |
| Repatha Sureclick | 37 | $24,503 | $662 |
| Ranolazine Er | 79 | $19,945 | $252 |
| Metoprolol | 730 | $17,852 | $24 |
| Rosuvastatin | 259 | $13,025 | $50 |
| Bumetanide | 147 | $11,572 | $79 |
| Brilinta | 18 | $8,938 | $497 |
| Livalo | 15 | $8,279 | $552 |
| Atorvastatin | 570 | $8,228 | $14 |
| Digoxin | 222 | $7,681 | $35 |
| Edarbyclor | 17 | $7,585 | $446 |
| Ezetimibe | 127 | $7,321 | $58 |
| Edarbi | 22 | $6,012 | $273 |
| Isosorbide Mononitrate Er | 296 | $4,809 | $16 |
| Potassium Chloride | 175 | $4,598 | $26 |
| Diltiazem 24hr Er (Cd) | 127 | $4,406 | $35 |
| Amlodipine Besylate | 554 | $4,008 | $7 |
| Carvedilol | 328 | $3,943 | $12 |
| Diovan | 13 | $3,530 | $272 |
| Dilt-Xr | 95 | $3,209 | $34 |
| Losartan | 391 | $3,074 | $8 |
| Valsartan | 52 | $2,744 | $53 |
| Furosemide | 356 | $2,467 | $7 |
| Nitroglycerin | 126 | $2,287 | $18 |
| Lisinopril | 282 | $2,163 | $8 |
| Olmesartan Medoxomil | 53 | $2,075 | $39 |
| Digox | 52 | $2,032 | $39 |
| Hydralazine | 138 | $2,023 | $15 |
| Omega-3 Acid Ethyl Esters | 16 | $2,008 | $126 |
| Valsartan-Hydrochlorothiazide | 50 | $2,003 | $40 |
| Losartan-Hydrochlorothiazide | 140 | $1,824 | $13 |
| Midodrine | 30 | $1,809 | $60 |
| Sotalol | 85 | $1,790 | $21 |
| Diltiazem 24hr Er | 43 | $1,751 | $41 |
| Fenofibrate | 31 | $1,615 | $52 |
| Amlodipine Besylate-Benazepril | 50 | $1,589 | $32 |
| Amiodarone | 74 | $1,507 | $20 |
| Flecainide Acetate | 18 | $1,497 | $83 |
| Clopidogrel | 82 | $1,455 | $18 |
| Cartia Xt | 52 | $1,448 | $28 |
| Spironolactone | 96 | $1,395 | $15 |
| Propafenone | 22 | $1,219 | $55 |
| Metoprolol | 109 | $1,135 | $10 |
| Diltiazem | 45 | $1,001 | $22 |
| Omeprazole | 45 | $898 | $20 |
| Telmisartan | 13 | $865 | $67 |
| Hydrochlorothiazide | 144 | $865 | $6 |
| Fenofibrate | 18 | $861 | $48 |
| Bisoprolol | 11 | $772 | $70 |
| Digitek | 13 | $745 | $57 |
| Cilostazol | 18 | $714 | $40 |
| Simvastatin | 83 | $685 | $8 |
| Isosorbide Dinitrate | 12 | $672 | $56 |
| Lisinopril-Hydrochlorothiazide | 38 | $573 | $15 |
| Chlorthalidone | 14 | $530 | $38 |
| Warfarin | 28 | $522 | $19 |
| Pantoprazole | 30 | $400 | $13 |
| Nitroglycerin Patch | 14 | $374 | $27 |
| Benazepril | 35 | $351 | $10 |
| Verapamil Er | 15 | $248 | $17 |
| Torsemide | 17 | $242 | $14 |
| Ramipril | 14 | $169 | $12 |
| Klor-Con 10 | 17 | $159 | $9 |
| Pravastatin | 16 | $136 | $9 |
| Atenolol | 14 | $118 | $8 |
2018: 73 drugs
| Eliquis | 473 | $272,727 | $577 |
| Ranexa | 168 | $78,183 | $465 |
| Xarelto | 103 | $54,787 | $532 |
| Bystolic | 214 | $40,747 | $190 |
| Entresto | 61 | $30,894 | $506 |
| Vascepa | 73 | $23,778 | $326 |
| Pradaxa | 44 | $23,443 | $533 |
| Metoprolol | 726 | $18,756 | $26 |
| Ezetimibe | 123 | $12,215 | $99 |
| Rosuvastatin | 285 | $11,514 | $40 |
| Bumetanide | 173 | $10,959 | $63 |
| Edarbyclor | 25 | $8,334 | $333 |
| Digoxin | 258 | $8,259 | $32 |
| Edarbi | 36 | $8,209 | $228 |
| Atorvastatin | 464 | $6,564 | $14 |
| Digox | 128 | $6,225 | $49 |
| Crestor | 17 | $6,075 | $357 |
| Brilinta | 13 | $5,573 | $429 |
| Isosorbide Mononitrate Er | 284 | $5,457 | $19 |
| Omega-3 Acid Ethyl Esters | 28 | $5,432 | $194 |
| Livalo | 15 | $5,360 | $357 |
| Valsartan | 120 | $4,969 | $41 |
| Vesicare | 11 | $4,486 | $408 |
| Potassium Chloride | 156 | $3,930 | $25 |
| Amlodipine Besylate | 553 | $3,897 | $7 |
| Carvedilol | 416 | $3,573 | $9 |
| Losartan | 411 | $3,221 | $8 |
| Diovan | 12 | $3,090 | $258 |
| Dilt-Xr | 88 | $2,968 | $34 |
| Cartia Xt | 116 | $2,947 | $25 |
| Diltiazem 24hr Er (Cd) | 83 | $2,558 | $31 |
| Nitroglycerin | 107 | $2,423 | $23 |
| Valsartan-Hydrochlorothiazide | 99 | $2,332 | $24 |
| Hydralazine | 178 | $2,323 | $13 |
| Olmesartan Medoxomil | 38 | $2,297 | $60 |
| Amlodipine-Valsartan-Hctz | 13 | $2,217 | $171 |
| Digitek | 48 | $2,023 | $42 |
| Fenofibric Acid | 14 | $1,990 | $142 |
| Furosemide | 384 | $1,913 | $5 |
| Lisinopril | 300 | $1,802 | $6 |
| Fenofibrate | 36 | $1,781 | $49 |
| Sotalol | 98 | $1,758 | $18 |
| Amiodarone | 110 | $1,723 | $16 |
| Losartan-Hydrochlorothiazide | 144 | $1,550 | $11 |
| Diltiazem 24hr Er | 37 | $1,492 | $40 |
| Fenofibrate | 37 | $1,485 | $40 |
| Clopidogrel | 80 | $1,470 | $18 |
| Metoprolol | 188 | $1,345 | $7 |
| Diltiazem | 86 | $1,323 | $15 |
| Simvastatin | 128 | $1,276 | $10 |
| Amlodipine Besylate-Benazepril | 63 | $1,269 | $20 |
| Spironolactone | 68 | $1,156 | $17 |
| Chlorthalidone | 29 | $1,041 | $36 |
| Omeprazole | 44 | $1,005 | $23 |
| Bisoprolol | 22 | $943 | $43 |
| Flecainide Acetate | 23 | $933 | $41 |
| Hydrochlorothiazide | 151 | $882 | $6 |
| Propafenone | 16 | $858 | $54 |
| Benazepril-Hydrochlorothiazide | 19 | $756 | $40 |
| Midodrine | 28 | $744 | $27 |
| Warfarin | 52 | $692 | $13 |
| Diltiazem 24hr Er (Xr) | 12 | $598 | $50 |
| Lisinopril-Hydrochlorothiazide | 35 | $516 | $15 |
| Olmesartan-Hydrochlorothiazide | 12 | $511 | $43 |
| Nitroglycerin Patch | 16 | $437 | $27 |
| Benazepril | 43 | $375 | $9 |
| Pantoprazole | 23 | $323 | $14 |
| Cilostazol | 13 | $305 | $23 |
| Pravastatin | 40 | $298 | $7 |
| Atenolol | 26 | $267 | $10 |
| Ramipril | 15 | $222 | $15 |
| Verapamil Er | 13 | $173 | $13 |
| Klor-Con 10 | 16 | $146 | $9 |
2017: 76 drugs
| Eliquis | 505 | $241,832 | $479 |
| Ranexa | 226 | $93,215 | $412 |
| Bystolic | 246 | $42,031 | $171 |
| Entresto | 79 | $36,141 | $457 |
| Xarelto | 70 | $34,490 | $493 |
| Vascepa | 95 | $28,310 | $298 |
| Pradaxa | 59 | $26,683 | $452 |
| Zetia | 72 | $24,637 | $342 |
| Metoprolol | 925 | $19,214 | $21 |
| Crestor | 44 | $14,824 | $337 |
| Edarbi | 47 | $11,849 | $252 |
| Rosuvastatin | 284 | $11,075 | $39 |
| Edarbyclor | 39 | $9,701 | $249 |
| Omega-3 Acid Ethyl Esters | 75 | $9,419 | $126 |
| Digoxin | 279 | $8,819 | $32 |
| Effient | 16 | $8,413 | $526 |
| Digox | 162 | $8,312 | $51 |
| Bumetanide | 173 | $8,061 | $47 |
| Ezetimibe | 61 | $7,809 | $128 |
| Atorvastatin | 592 | $7,338 | $12 |
| Valsartan | 208 | $6,586 | $32 |
| Brilinta | 19 | $6,294 | $331 |
| Benicar | 17 | $6,034 | $355 |
| Fenofibric Acid | 43 | $5,757 | $134 |
| Isosorbide Mononitrate Er | 337 | $5,629 | $17 |
| Potassium Chloride | 227 | $4,545 | $20 |
| Fenofibrate | 49 | $4,089 | $83 |
| Diltiazem 24hr Er | 184 | $4,082 | $22 |
| Livalo | 16 | $4,030 | $252 |
| Amlodipine Besylate | 694 | $4,003 | $6 |
| Carvedilol | 530 | $3,571 | $7 |
| Niacin Er | 14 | $3,557 | $254 |
| Valsartan-Hydrochlorothiazide | 168 | $3,433 | $20 |
| Cartia Xt | 160 | $3,269 | $20 |
| Digitek | 102 | $3,103 | $30 |
| Diovan | 12 | $2,803 | $234 |
| Losartan | 442 | $2,664 | $6 |
| Dilt-Xr | 78 | $2,417 | $31 |
| Nitroglycerin | 89 | $2,250 | $25 |
| Lisinopril | 394 | $2,229 | $6 |
| Sotalol | 124 | $2,185 | $18 |
| Hydralazine | 220 | $2,161 | $10 |
| Furosemide | 390 | $1,891 | $5 |
| Amlodipine Besylate-Benazepril | 72 | $1,880 | $26 |
| Amlodipine-Valsartan-Hctz | 16 | $1,828 | $114 |
| Amiodarone | 60 | $1,736 | $29 |
| Isosorbide Dinitrate | 13 | $1,478 | $114 |
| Benazepril-Hydrochlorothiazide | 22 | $1,436 | $65 |
| Olmesartan Medoxomil | 14 | $1,367 | $98 |
| Simvastatin | 165 | $1,324 | $8 |
| Fenofibrate | 47 | $1,174 | $25 |
| Diltiazem Er | 36 | $1,150 | $32 |
| Nitroglycerin Patch | 41 | $1,110 | $27 |
| Flecainide Acetate | 33 | $1,091 | $33 |
| Spironolactone | 94 | $991 | $11 |
| Metoprolol | 161 | $967 | $6 |
| Clopidogrel | 64 | $939 | $15 |
| Sotalol Af | 18 | $879 | $49 |
| Diltiazem | 72 | $845 | $12 |
| Chlorthalidone | 25 | $756 | $30 |
| Hydrochlorothiazide | 144 | $637 | $4 |
| Toprol Xl | 13 | $589 | $45 |
| Propafenone | 12 | $577 | $48 |
| Fenofibrate | 11 | $549 | $50 |
| Losartan-Hydrochlorothiazide | 52 | $543 | $10 |
| Pravastatin | 41 | $533 | $13 |
| Omeprazole | 44 | $533 | $12 |
| Cilostazol | 29 | $529 | $18 |
| Warfarin | 53 | $492 | $9 |
| Benazepril | 70 | $473 | $7 |
| Lisinopril-Hydrochlorothiazide | 49 | $349 | $7 |
| Quinapril | 16 | $278 | $17 |
| Pantoprazole | 26 | $238 | $9 |
| Klor-Con 10 | 17 | $216 | $13 |
| Ramipril | 15 | $206 | $14 |
| Atenolol | 44 | $199 | $5 |
2016: 89 drugs
| Eliquis | 506 | $210,102 | $415 |
| Ranexa | 285 | $100,130 | $351 |
| Crestor | 206 | $67,230 | $326 |
| Bystolic | 298 | $42,136 | $141 |
| Pradaxa | 85 | $34,808 | $410 |
| Zetia | 87 | $28,535 | $328 |
| Metoprolol | 1,002 | $19,591 | $20 |
| Vascepa | 69 | $19,361 | $281 |
| Omega-3 Acid Ethyl Esters | 113 | $18,354 | $162 |
| Xarelto | 37 | $15,496 | $419 |
| Edarbi | 70 | $14,364 | $205 |
| Edarbyclor | 64 | $12,575 | $196 |
| Valsartan | 264 | $11,881 | $45 |
| Benicar | 39 | $10,965 | $281 |
| Effient | 21 | $10,297 | $490 |
| Atorvastatin | 773 | $9,887 | $13 |
| Digoxin | 301 | $8,658 | $29 |
| Rosuvastatin | 91 | $8,050 | $88 |
| Livalo | 27 | $7,759 | $287 |
| Veltassa | 12 | $7,498 | $625 |
| Benicar Hct | 22 | $7,444 | $338 |
| Fenofibric Acid | 59 | $6,154 | $104 |
| Niacin Er | 31 | $6,069 | $196 |
| Diltiazem 24hr Er | 253 | $6,012 | $24 |
| Vytorin | 21 | $5,757 | $274 |
| Isosorbide Mononitrate Er | 420 | $5,714 | $14 |
| Digox | 127 | $5,553 | $44 |
| Fenofibrate | 50 | $5,430 | $109 |
| Amlodipine Besylate | 963 | $5,238 | $5 |
| Bumetanide | 115 | $5,184 | $45 |
| Carvedilol | 733 | $5,100 | $7 |
| Amlodipine-Valsartan-Hctz | 38 | $4,973 | $131 |
| Potassium Chloride | 226 | $4,971 | $22 |
| Entresto | 12 | $4,814 | $401 |
| Hydralazine | 328 | $4,403 | $13 |
| Brilinta | 12 | $3,792 | $316 |
| Valsartan-Hydrochlorothiazide | 207 | $3,784 | $18 |
| Azor | 12 | $3,527 | $294 |
| Amlodipine Besylate-Benazepril | 162 | $3,506 | $22 |
| Diovan | 18 | $3,396 | $189 |
| Losartan | 530 | $3,214 | $6 |
| Amlodipine-Valsartan | 31 | $3,100 | $100 |
| Lanoxin | 11 | $2,968 | $270 |
| Cartia Xt | 100 | $2,710 | $27 |
| Dilt-Xr | 76 | $2,547 | $34 |
| Nitroglycerin | 27 | $2,495 | $92 |
| Lisinopril | 387 | $2,344 | $6 |
| Furosemide | 441 | $1,934 | $4 |
| Fenofibrate | 33 | $1,834 | $56 |
| Isosorbide Dinitrate | 28 | $1,781 | $64 |
| Nitrostat | 63 | $1,599 | $25 |
| Simvastatin | 217 | $1,529 | $7 |
| Digitek | 56 | $1,479 | $26 |
| Diltiazem Er | 39 | $1,394 | $36 |
| Sotalol | 122 | $1,392 | $11 |
| Clopidogrel | 104 | $1,366 | $13 |
| Propranolol Hcl Er | 15 | $1,317 | $88 |
| Fenofibrate | 53 | $1,317 | $25 |
| Metoprolol | 240 | $1,168 | $5 |
| Diltiazem | 117 | $1,104 | $9 |
| Nitroglycerin Patch | 42 | $1,062 | $25 |
| Benazepril-Hydrochlorothiazide | 24 | $1,048 | $44 |
| Toprol Xl | 22 | $987 | $45 |
| Diltiazem 24hr Cd | 35 | $940 | $27 |
| Verapamil Er | 26 | $914 | $35 |
| Pravastatin | 55 | $898 | $16 |
| Captopril | 16 | $897 | $56 |
| Flecainide Acetate | 31 | $741 | $24 |
| Omeprazole | 67 | $726 | $11 |
| Amiodarone | 52 | $692 | $13 |
| Propafenone | 13 | $633 | $49 |
| Spironolactone | 63 | $628 | $10 |
| Hydrochlorothiazide | 156 | $625 | $4 |
| Benazepril | 101 | $604 | $6 |
| Cilostazol | 42 | $576 | $14 |
| Warfarin | 56 | $571 | $10 |
| Midodrine | 16 | $563 | $35 |
| Quinapril-Hydrochlorothiazide | 11 | $554 | $50 |
| Nifedipine Er | 13 | $503 | $39 |
| Losartan-Hydrochlorothiazide | 50 | $492 | $10 |
| Enalapril Maleate | 14 | $441 | $31 |
| Famotidine | 13 | $322 | $25 |
| Atenolol | 62 | $250 | $4 |
| Lisinopril-Hydrochlorothiazide | 42 | $222 | $5 |
| Sotalol Af | 14 | $190 | $14 |
| Ranitidine | 22 | $182 | $8 |
| Ramipril | 11 | $105 | $10 |
| Pantoprazole | 14 | $98 | $7 |
| Enalapril-Hydrochlorothiazide | 12 | $88 | $7 |
2015: 81 drugs
| Eliquis | 491 | $179,269 | $365 |
| Crestor | 235 | $71,409 | $304 |
| Ranexa | 218 | $62,171 | $285 |
| Bystolic | 282 | $42,117 | $149 |
| Pradaxa | 60 | $23,541 | $392 |
| Metoprolol | 972 | $22,910 | $24 |
| Omega-3 Acid Ethyl Esters | 97 | $22,769 | $235 |
| Zetia | 82 | $21,526 | $263 |
| Valsartan | 275 | $18,494 | $67 |
| Lanoxin | 95 | $12,827 | $135 |
| Niacin Er | 38 | $12,764 | $336 |
| Xarelto | 33 | $12,154 | $368 |
| Edarbyclor | 57 | $10,993 | $193 |
| Vascepa | 42 | $10,861 | $259 |
| Edarbi | 59 | $10,147 | $172 |
| Atorvastatin | 693 | $8,364 | $12 |
| Effient | 16 | $7,306 | $457 |
| Benicar Hct | 27 | $6,893 | $255 |
| Valsartan-Hydrochlorothiazide | 223 | $6,708 | $30 |
| Benicar | 31 | $6,705 | $216 |
| Vytorin | 25 | $6,184 | $247 |
| Potassium Chloride | 202 | $5,501 | $27 |
| Digoxin | 157 | $5,283 | $34 |
| Amlodipine Besylate-Benazepril | 181 | $5,170 | $29 |
| Fenofibric Acid | 47 | $4,954 | $105 |
| Exforge Hct | 21 | $4,949 | $236 |
| Diovan | 31 | $4,784 | $154 |
| Fenofibrate | 36 | $4,773 | $133 |
| Bumetanide | 90 | $4,748 | $53 |
| Exforge | 13 | $4,336 | $334 |
| Isosorbide Mononitrate Er | 362 | $4,335 | $12 |
| Amlodipine Besylate | 815 | $4,330 | $5 |
| Carvedilol | 660 | $4,126 | $6 |
| Dexilant | 13 | $4,102 | $316 |
| Diltiazem 24hr Er | 162 | $4,019 | $25 |
| Digox | 84 | $3,952 | $47 |
| Azor | 16 | $3,646 | $228 |
| Amlodipine-Valsartan | 31 | $2,742 | $88 |
| Nitroglycerin | 11 | $2,706 | $246 |
| Fenofibrate | 31 | $2,622 | $85 |
| Diltiazem Er | 72 | $2,366 | $33 |
| Hydralazine | 205 | $2,322 | $11 |
| Losartan | 407 | $2,320 | $6 |
| Dilt-Xr | 57 | $2,212 | $39 |
| Lisinopril | 408 | $1,957 | $5 |
| Diltiazem 24hr Cd | 73 | $1,847 | $25 |
| Fenofibrate | 47 | $1,633 | $35 |
| Cartia Xt | 75 | $1,606 | $21 |
| Furosemide | 344 | $1,582 | $5 |
| Simvastatin | 253 | $1,436 | $6 |
| Sotalol | 136 | $1,396 | $10 |
| Benazepril-Hydrochlorothiazide | 20 | $1,308 | $65 |
| Warfarin | 93 | $1,214 | $13 |
| Toprol Xl | 22 | $942 | $43 |
| Cilostazol | 49 | $928 | $19 |
| Digitek | 23 | $890 | $39 |
| Nitroglycerin Patch | 32 | $877 | $27 |
| Spironolactone | 95 | $865 | $9 |
| Propafenone | 12 | $816 | $68 |
| Nitrostat | 51 | $812 | $16 |
| Hydrochlorothiazide | 184 | $779 | $4 |
| Metoprolol | 167 | $753 | $5 |
| Clopidogrel | 64 | $683 | $11 |
| Diltiazem | 82 | $660 | $8 |
| Pravastatin | 33 | $607 | $18 |
| Captopril | 11 | $600 | $55 |
| Losartan-Hydrochlorothiazide | 69 | $598 | $9 |
| Omeprazole | 78 | $597 | $8 |
| Verapamil Er | 36 | $584 | $16 |
| Flecainide Acetate | 14 | $578 | $41 |
| Propranolol Hcl Er | 11 | $543 | $49 |
| Amiodarone | 58 | $534 | $9 |
| Taztia Xt | 21 | $438 | $21 |
| Benazepril | 72 | $433 | $6 |
| Quinapril-Hydrochlorothiazide | 12 | $387 | $32 |
| Lisinopril-Hydrochlorothiazide | 44 | $263 | $6 |
| Atenolol | 45 | $235 | $5 |
| Famotidine | 12 | $173 | $14 |
| Ranitidine | 22 | $147 | $7 |
| Sotalol Af | 11 | $126 | $11 |
| Pantoprazole | 13 | $62 | $5 |
2014: 77 drugs
| Eliquis | 344 | $116,491 | $339 |
| Crestor | 290 | $78,854 | $272 |
| Diovan | 268 | $46,428 | $173 |
| Ranexa | 152 | $42,518 | $280 |
| Bystolic | 215 | $24,637 | $115 |
| Metoprolol | 845 | $24,118 | $29 |
| Lovaza | 76 | $23,679 | $312 |
| Pradaxa | 55 | $19,721 | $359 |
| Niacin Er | 58 | $18,383 | $317 |
| Exforge | 61 | $13,889 | $228 |
| Xarelto | 47 | $13,653 | $290 |
| Zetia | 53 | $12,370 | $233 |
| Valsartan-Hydrochlorothiazide | 240 | $9,757 | $41 |
| Edarbyclor | 57 | $8,672 | $152 |
| Atorvastatin | 567 | $8,568 | $15 |
| Fenofibric Acid | 63 | $8,288 | $132 |
| Azor | 35 | $7,731 | $221 |
| Edarbi | 50 | $7,559 | $151 |
| Exforge Hct | 31 | $7,476 | $241 |
| Fenofibrate | 47 | $7,314 | $156 |
| Amlodipine Besylate-Benazepril | 149 | $7,021 | $47 |
| Vytorin | 29 | $6,939 | $239 |
| Omega-3 Acid Ethyl Esters | 30 | $6,056 | $202 |
| Benicar Hct | 30 | $5,993 | $200 |
| Diltiazem 24hr Er | 188 | $5,718 | $30 |
| Effient | 15 | $5,671 | $378 |
| Valsartan | 38 | $5,625 | $148 |
| Carvedilol | 675 | $5,573 | $8 |
| Fenofibrate | 43 | $5,295 | $123 |
| Diltiazem 24hr Cd | 57 | $4,702 | $82 |
| Dexilant | 19 | $4,338 | $228 |
| Amlodipine Besylate | 626 | $4,016 | $6 |
| Lanoxin | 49 | $4,013 | $82 |
| Digox | 85 | $3,710 | $44 |
| Potassium Chloride | 123 | $3,699 | $30 |
| Isosorbide Mononitrate Er | 263 | $3,579 | $14 |
| Digoxin | 101 | $3,448 | $34 |
| Diltiazem Er | 103 | $3,123 | $30 |
| Hydralazine | 178 | $3,109 | $17 |
| Lisinopril | 370 | $2,201 | $6 |
| Losartan | 223 | $2,152 | $10 |
| Bumetanide | 78 | $1,939 | $25 |
| Simvastatin | 287 | $1,881 | $7 |
| Furosemide | 349 | $1,563 | $4 |
| Fenofibrate | 23 | $1,332 | $58 |
| Warfarin | 126 | $1,244 | $10 |
| Cilostazol | 52 | $1,242 | $24 |
| Nadolol | 19 | $1,204 | $63 |
| Sotalol | 62 | $1,195 | $19 |
| Pravastatin | 37 | $1,146 | $31 |
| Metoprolol | 151 | $1,006 | $7 |
| Dilt-Xr | 13 | $967 | $74 |
| Benazepril-Hydrochlorothiazide | 18 | $930 | $52 |
| Spironolactone | 111 | $876 | $8 |
| Clopidogrel | 79 | $839 | $11 |
| Cartia Xt | 32 | $765 | $24 |
| Hydrochlorothiazide | 173 | $714 | $4 |
| Omeprazole | 69 | $668 | $10 |
| Nitrostat | 52 | $656 | $13 |
| Losartan-Hydrochlorothiazide | 61 | $606 | $10 |
| Toprol Xl | 14 | $575 | $41 |
| Diltiazem | 78 | $531 | $7 |
| Pantoprazole | 13 | $515 | $40 |
| Amiodarone | 19 | $485 | $26 |
| Benazepril | 54 | $483 | $9 |
| Captopril | 12 | $437 | $36 |
| Meclizine | 16 | $437 | $27 |
| Lisinopril-Hydrochlorothiazide | 61 | $430 | $7 |
| Nitroglycerin Patch | 17 | $406 | $24 |
| Klor-Con 10 | 14 | $374 | $27 |
| Verapamil Er | 12 | $361 | $30 |
| Taztia Xt | 15 | $317 | $21 |
| Atenolol | 34 | $306 | $9 |
| Torsemide | 15 | $209 | $14 |
| Klor-Con M10 | 12 | $186 | $15 |
| Famotidine | 15 | $143 | $10 |
| Ranitidine | 13 | $129 | $10 |
2013: 81 drugs
| Tracleer | 11 | $76,977 | $6,998 |
| Crestor | 318 | $67,640 | $213 |
| Eliquis | 133 | $40,450 | $304 |
| Diovan | 280 | $40,413 | $144 |
| Niaspan | 97 | $29,264 | $302 |
| Lovaza | 104 | $25,577 | $246 |
| Pradaxa | 74 | $25,005 | $338 |
| Metoprolol | 691 | $21,230 | $31 |
| Bystolic | 229 | $20,443 | $89 |
| Ranexa | 59 | $19,152 | $325 |
| Diovan Hct | 87 | $13,287 | $153 |
| Exforge | 78 | $11,760 | $151 |
| Zetia | 58 | $11,376 | $196 |
| Amlodipine Besylate-Benazepril | 197 | $11,198 | $57 |
| Valsartan-Hydrochlorothiazide | 154 | $10,911 | $71 |
| Vytorin | 43 | $10,742 | $250 |
| Atorvastatin | 338 | $9,563 | $28 |
| Fenofibrate | 52 | $8,695 | $167 |
| Trilipix | 49 | $7,993 | $163 |
| Carvedilol | 679 | $7,162 | $11 |
| Xarelto | 29 | $7,142 | $246 |
| Azor | 33 | $6,297 | $191 |
| Edarbyclor | 39 | $5,472 | $140 |
| Diltiazem 24hr Cd | 72 | $4,630 | $64 |
| Diltiazem 24hr Er | 144 | $4,563 | $32 |
| Benicar | 26 | $4,455 | $171 |
| Amlodipine Besylate | 571 | $4,389 | $8 |
| Clopidogrel | 68 | $4,242 | $62 |
| Niacin Er | 15 | $4,222 | $281 |
| Micardis Hct | 22 | $4,065 | $185 |
| Isosorbide Mononitrate Er | 222 | $3,926 | $18 |
| Welchol | 11 | $3,540 | $322 |
| Hydralazine | 156 | $3,534 | $23 |
| Benicar Hct | 21 | $3,492 | $166 |
| Potassium Chloride | 96 | $3,241 | $34 |
| Dexilant | 14 | $3,194 | $228 |
| Edarbi | 26 | $3,149 | $121 |
| Diltiazem Er | 97 | $3,109 | $32 |
| Exforge Hct | 16 | $2,903 | $181 |
| Lisinopril | 337 | $2,458 | $7 |
| Simvastatin | 306 | $2,449 | $8 |
| Antara | 14 | $2,343 | $167 |
| Fenofibric Acid | 18 | $2,220 | $123 |
| Losartan | 146 | $2,064 | $14 |
| Warfarin | 221 | $1,992 | $9 |
| Fenofibrate | 28 | $1,879 | $67 |
| Furosemide | 379 | $1,809 | $5 |
| Cartia Xt | 48 | $1,799 | $37 |
| Isosorbide Dinitrate | 18 | $1,735 | $96 |
| Cilostazol | 46 | $1,384 | $30 |
| Digox | 109 | $1,278 | $12 |
| Lanoxin | 16 | $923 | $58 |
| Metoprolol | 131 | $919 | $7 |
| Spironolactone | 103 | $864 | $8 |
| Losartan-Hydrochlorothiazide | 40 | $811 | $20 |
| Omeprazole | 50 | $783 | $16 |
| Hydrochlorothiazide | 160 | $769 | $5 |
| Pravastatin | 35 | $738 | $21 |
| Toprol Xl | 15 | $732 | $49 |
| Bumetanide | 43 | $683 | $16 |
| Lisinopril-Hydrochlorothiazide | 71 | $655 | $9 |
| Pantoprazole | 23 | $646 | $28 |
| Fenofibrate | 12 | $630 | $52 |
| Quinapril-Hydrochlorothiazide | 12 | $627 | $52 |
| Benazepril | 56 | $600 | $11 |
| Sotalol | 39 | $599 | $15 |
| Verapamil Er | 18 | $494 | $27 |
| Torsemide | 20 | $464 | $23 |
| Diltiazem | 65 | $445 | $7 |
| Amiodarone | 11 | $404 | $37 |
| Digoxin | 46 | $379 | $8 |
| Nitroglycerin Patch | 15 | $367 | $24 |
| Ramipril | 21 | $288 | $14 |
| Nitrostat | 25 | $286 | $11 |
| Atenolol | 40 | $261 | $7 |
| Benazepril-Hydrochlorothiazide | 11 | $212 | $19 |
| Fosinopril | 14 | $174 | $12 |
| Klor-Con M10 | 11 | $160 | $15 |
| Famotidine | 11 | $131 | $12 |
| Niacor | 11 | $119 | $11 |
| Captopril | 13 | $85 | $7 |
Money from drug and device companies
$167 in 2025
| 2025 | 1 | 1 | None | $167 |
| 2024 | 2 | 3 | None | $103 |
| 2023 | 3 | 4 | None | $125 |
| 2022 | 6 | 15 | None | $531 |
| 2021 | 3 | 4 | None | $56 |
| 2020 | 4 | 8 | None | $244 |
| 2019 | 7 | 50 | None | $578 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik | Amvia Edge | $167 | 1 payment
|
See the published payment
| Biotronik | Meals · 2025-09-18 | Amvia Edge | $167 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $103
| Abbott Laboratories | Coroflow | $75 | 2 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $28 | 1 payment
|
2023: $125
| Merck Sharp & Dohme | Verquvo | $83 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $34 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $8 | 1 payment
|
2022: $531
| E.R. Squibb & Sons L.L.C. | Eliquis | $221 | 7 payments
|
| Biotronik | Biomonitor | $159 | 1 payment
|
| Abbott Laboratories | Mitraclip | $63 | 2 payments
|
| Boston Scientific | Watchman Access System | $46 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $28 | 2 payments
|
| Pfizer | Eliquis | $14 | 1 payment
|
2021: $56
| Novartis Pharmaceuticals | Entresto | $22 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $22 | 1 payment
|
| Biotronik | Solia | $12 | 1 payment
|
2020: $244
| Medtronic Vascular | Heartware Hvad | $173 | 3 payments
|
| Biotronik | None | $38 | 3 payments
|
| Amgen | Repatha | $17 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $17 | 1 payment
|
2019: $578
| Pfizer | Vyndaqel | $245 | 20 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $163 | 23 payments
|
| Amgen | Repatha | $68 | 2 payments
|
| Medtronic Vascular | Reveal Linq | $42 | 2 payments
|
| Akcea Therapeutics | Tegsedi | $33 | 1 payment
|
| Lundbeck | Northera | $18 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $11 | 1 payment
|
Checkups this office reported
8 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 83.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 776 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 99%That's most of the people this applied to. | 1,027 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 63%That's more than half. | 640 |
| Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF <= 40%)As Medicare defines this measure | 100% | 157 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 4,788 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 98%That's most of the people this applied to. | 724 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 2,306 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 1,188 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- ONC-ACB Surveillance Attestation
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1952597478
- Licence
- CA 7322-43, CA A55594California A55594: Current · expires 2028-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Federal specialty code 207UN0901X (207UN0901X)
- Mailing address
- 18511 Mission View Dr, Suite 120, Morgan Hill, CA, 95037
- NPI first listed
- 2007-09-18
- NPI last updated
- 2024-04-18
- NPI record certified
- 2024-04-14
This is when the NPI record was last certified, not a medical board exam.